Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed ileal, ileo-colonic, or colonic CD at least 6 months prior to screening.~* Men or women age 18 - 65 years at the time of screening.~* Moderate-sever active Crohn's Disease (CD), defined by a Crohn's Disease Activity Index (CDAI) score higher or equal 220 and lower or equal 450 at Day 1.~* No known history of active tuberculosis (TB).~* Received at least one anti-TNFα agent for the treatment of CD and did not initially respond.~Exclusion Criteria:~* Pregnant or breastfeeding women.~* Presence of ileostomy and/or colostomy.~* Short bowel syndrome.~* Bowel perforation or obstruction.~* History of cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MEDI2070 iv infusion
- 2 (Type: PLACEBO_COMPARATOR): placebo iv infusion
- open-label (Type: EXPERIMENTAL): MEDI2070 sc injection; open-label arm is available for all subjects upon completion of first placebo-controlled treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).